Fingerprint
Dive into the research topics of 'Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
John Radford, Andrew Davies*, Guillaume Cartron, Franck Morschhauser, Gilles Salles, Robert Marcus, Michael Wenger, Guiyuan Lei, Elisabeth Wassner-Fritsch, Umberto Vitolo
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
114
Citations
(Scopus)